SCHEMBL1745272

SCHEMBL1745272

O=C(O)CCc1ccc(OC2CCc3cc(-c4ccc(F)cc4)ccc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 11/20 0.49
GFRA3 O60609 1/20 0.45
RET P07949 1/20 0.45
FFAR1 O14842 10/20 0.44
EPHX2 P34913 1/20 0.44
AKR1B1 P15121 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744798 0.91 FFAR1 (0.53) FFAR4GFRA3RETFFAR1AKR1B1
SCHEMBL1747354 0.91 FFAR4 (0.48) FFAR4GFRA3RETFFAR1EPHX2
SCHEMBL1744979 0.89 FFAR1 (0.54) FFAR4GFRA3RETFFAR1AKR1B1
SCHEMBL1746742 0.89 GFRA3 (0.45) FFAR4GFRA3RETFFAR1AKR1B1
SCHEMBL1745473 0.89 FFAR1 (0.48) FFAR4GFRA3RETFFAR1AKR1B1
SCHEMBL1746658 0.89 FFAR4 (0.46) FFAR4GFRA3RETFFAR1PPARG
SCHEMBL14567251 0.84 FFAR1 (0.50) FFAR4GFRA3RETFFAR1AKR1B1
SCHEMBL1745543 0.83 FFAR1 (0.51) FFAR4GFRA3RETFFAR1AKR1B1
SCHEMBL1746586 0.82 FFAR1 (0.46) FFAR4FFAR1PPARGPPARA
SCHEMBL1745475 0.82 FFAR1 (0.50) FFAR4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR4 44/4885GFRA3 412/4885RET 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.